A Phase 3 interventional study of olaparib and abiraterone acetate in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Active, not recruiting at 26 sites in China. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.
Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 7th largest by enrollment, is one of 3 that started in 2021, is one of 4 in phase 3, reaches primary completion later than 2 of the 10 other live ones, and was the 18th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Zin W Myint · Sites in United States
Ages 18+ · Men only
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 99 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 4 · Phase 4 1
First in 2014; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 43 across the 25 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 25 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
91 studies in Prostatic Neoplasms by AstraZeneca: 15 open now, 29 under way, 8 of them phase 3. Of 58 finished, 11 (19%) have results posted.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 30th largest by enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2021, is one of 17 in phase 3, reaches primary completion later than 1 of the 28 other live ones, and was the 63rd registered.
AstraZeneca’s Prostatic Neoplasms studies by the year they started, since 1994.
2 of the studies testing olaparib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04038502VA Office of Research and DevelopmentCarboplatin or Olaparib for BRcA Deficient Prostate Cancer | 2027-08-31 |
| NCT02861573Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | 2027-10-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies testing olaparib in Prostatic Neoplasms, from their registry updates:
Among AstraZeneca’s 91 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
PROpel is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting).
Approximately 720 patients globally were planned to be randomized in PROpel in a 1:1 ratio to treatment with either olaparib and abiraterone or placebo and abiraterone. Enrolment had completed with a total of 796 patients randomised. Following the completion of global enrolment, the China cohort will randomise approximately 108 additional patients at sites in China, also in a 1:1 ratio.
This cohort will enable standalone safety and efficacy analyses to support Chinese regulatory requirements. Patients from China will not be included in the Full Analysis Set for the global study analysis. In addition, all of the statistical analyses defined in this SAP will be performed using all patients randomised at sites in Asian countries (South Korea and Japan) excluding China, to be designated the Asian subgroup analysis.
Patients will receive oral treatment with olaparib 300 mg twice daily + abiraterone 1000 mg once daily or placebo twice daily + abiraterone 1000 mg once daily. Patients in both treatment groups will also receive either prednisone or prednisolone 5 mg twice daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For inclusion in i) the optional exploratory genetic research and ii) the optional biomarker research, patients must fulfill the following criteria:
If a patient declines to participate in the optional exploratory genetic research or the optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study. Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily.
Drug: olaparib · Drug: abiraterone acetate
Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study. Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily.
Drug: abiraterone acetate
300 mg (2 x 150 milligrams (mg) tablets) twice daily
Also known as: Lynparza
1000 milligrams (mg) once daily
Also known as: Zytiga
Radiological Progression Free Survival (rPFS)
Radiological progression free survival is defined as the time from randomisation until the earlier date of radiological progression or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression. Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute ≥ 5mm increase from nadir, and/or unequivocal progression in any non target lesions, and/or any new lesion identified. Per PCWG3, progression on a bone scan is defined as 2 or more new lesions observed from the first visit after baseline compared to baseline, or from all other visits compared to first visit after baseline. A confirmatory scan is required.
Time frame: Tumour imaging CT/MRI and bone scan were assessed every 8 weeks from randomisation to week 24 and then every 12 weeks until RECIST progression. Patients were followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum
Overall Survival (OS)
Overall survival is defined as the time from date of randomisation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy. The 22Jan2024 DCO is the final data cut-off for the OS analysis and therefore no further updates will be made.
Time frame: Assessed every 12 weeks from randomisation until death or data cut-off. The endpoint was followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum.
Time to First Subsequent Anticancer Therapy or Death (TFST)
Time to first subsequent anticancer therapy (excluding radiotherapy) is defined as the time from randomisation to the earlier of start date of the first subsequent anti cancer therapy after discontinuation of randomised treatment or death from any cause.
Time frame: Assessed from from randomization on 30 day follow-up after last dose of study medication and every 12 weeks after that until DCO. The endpoint was followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum.
Time to Pain Progression (TTPP)
Time to pain progression is defined as time from randomisation to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" (range 0-10, a higher score indicates worse pain) and opiate analgesic use (Analgesic quantification algorithm \[AQA\] score, range 0-7, a higher score indicates increased opioid use). For patients who are asymptomatic at baseline: A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits or initiation of opioid use; For patients who are symptomatic at baseline: A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits and an average worst pain score ≥4, and no decrease in average opioid use (≥1-point decrease in AQA score from a starting value of ≥2), or increase in opioid use (≥1-point increase, or ≥2-point increase if the starting value is 0) at 2 consecutive follow-up visits.
Time frame: The BPI-SF and AQA were assessed on screening, day 1, day 15, day 29, day 43, day 57, day 71, and every 4 weeks after week 13 until DCO. The endpoint was followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum.
Time to Opiate Use
Time to opiate use is defined as the time from date of randomisation to the date of first opiate use for cancer related pain.
Time frame: Assessed on screening, days 1, 29, and 57, every 4 weeks after week 13, treatment discontinuation, and 30-day follow-up after last dose of study medication. Followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum.
Time to a Symptomatic Skeletal-Related Event (SSRE)
Time from date of randomisation to date of first symptomatic skeletal-related event as defined by any of the following or a combination: * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). * Occurrence of spinal cord compression. * Orthopaedic surgical intervention for bone metastasis.
Time frame: Assessed at every visit from randomisation up to and including treatment discontinuation visit. The endpoint was followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum.
Time to Second Progression or Death (PFS2)
The time to PFS2 is defined as the time from date of randomisation to date of second progression on next-line (immediately after study treatment) anticancer therapy or death, whichever occurs earlier.
Time frame: Assessed from randomization every 12 weeks following the progression event used for PFS and the start of the next-line anticancer therapy. The endpoint was followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum.
Change From Baseline in BPI-SF Pain Severity and Pain Interference
All BPI-SF pain items including "worst pain" are scored on a 0-10 numeric rating scale (NRS) with 0=No Pain and 10=Worst Pain Imaginable. The pain severity domain consists of 4 items (item #3, item #4, item #5, and item #6) which assess pain at its "worst," "least," "average," and "now" (current pain) respectively on the 11-point NRS. The overall pain severity score is calculated for each patient/visit as the mean of the individual non-missing items. The pain interference domain score is a mean of 7 items: general activity (item #9A), mood (item #9B), walking ability (item #9C), normal work (item #9D), relations with other people (item #9E), sleep (item #9F), and enjoyment of life (item #9G), each scored on an 11-point NRS from 0 (Does not interfere) to 10 (Completely interferes). BPI-SF worst pain, pain severity and pain interference score changes can be a minimum of -10 and a maximum of 10. A negative change from baseline value indicates improvement.
Time frame: Assessed from date of first subject randomised: 23Jul2021 to data cut off (China DCO): 22Jan2024 (913 days). BPI-SF were completed by patients daily for 7 consecutive days every 4 weeks. Change from baseline is reported every 4 weeks until week 49.
Change From Baseline in Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P)
The following measures are calculated from the FACT-P questionnaire, the resulting value is the total score for the associated questions or scaled scores: * Physical well-being subscale (PWB) (Questions GP1 to GP7) * Social/family well-being subscale (SWB) (Questions GS1 to GS7) * Emotional well-being subscale (EWB) (Questions GE1 to GE6) * Functional well-being subscale (FWB) (Questions GF1 to GF7) * Prostate cancer subscale (PCS) (Questions C2, C6, P1 to P8, BL2 and BL5) The scores range from 0 ("Not at all") to 4 ("Very much") for positively phrased questions, and from 0 ("Very much") to 4 ("Not at all") for negatively phrased questions. Total FACT-P score is the sum of PWB, SWB, EWB, FWB and PCS. FACT-P total score changes can be a minimum of -156 and a maximum of 156. A positive value indicates improvement. FACT-G total score is the sum of PWB, SWB, EWB and FWB. FACT-G Total score changes can be a minimum of -108 and a maximum of 108. A positive value indicates improvement.
Time frame: Assessed from date of first subject randomised: 23Jul2021 to data cut off (China DCO): 22Jan2024 (913 days). FACT-P were assessed every 4 weeks from Day 1 until Week 52. Change from baseline is reported every 4 weeks until week 49.
Approximately 108 patients were planned to be randomized in the study. Actually 162 patients were screened, and 110 patients were randomized successfully.
| Milestone | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Started | 54 | 56 |
| Completed | 36 | 40 |
| Not completed | 18 | 16 |
| Withdrew: Death | 18 | 16 |
Radiological progression free survival is defined as the time from randomisation until the earlier date of radiological progression or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression. Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute ≥ 5mm increase from nadir, and/or unequivocal progression in any non target lesions, and/or any new lesion identified. Per PCWG3, progression on a bone scan is defined as 2 or more new lesions observed from the first visit after baseline compared to baseline, or from all other visits compared to first visit after baseline. A confirmatory scan is required.
| Months | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Radiological Progression Free Survival (rPFS) | 14.75 (12.06 to 22.11) | NA (NA to NA) |
Overall survival is defined as the time from date of randomisation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy. The 22Jan2024 DCO is the final data cut-off for the OS analysis and therefore no further updates will be made.
| Months | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Overall Survival (OS) | 27.83 (27.83 to NA) | NA (NA to NA) |
Time to first subsequent anticancer therapy (excluding radiotherapy) is defined as the time from randomisation to the earlier of start date of the first subsequent anti cancer therapy after discontinuation of randomised treatment or death from any cause.
| Months | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Time to First Subsequent Anticancer Therapy or Death (TFST) | 19.1 (15.4 to NA) | 17.6 (10.6 to NA) |
Time to pain progression is defined as time from randomisation to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" (range 0-10, a higher score indicates worse pain) and opiate analgesic use (Analgesic quantification algorithm \[AQA\] score, range 0-7, a higher score indicates increased opioid use). For patients who are asymptomatic at baseline: A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits or initiation of opioid use; For patients who are symptomatic at baseline: A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits and an average worst pain score ≥4, and no decrease in average opioid use (≥1-point decrease in AQA score from a starting value of ≥2), or increase in opioid use (≥1-point increase, or ≥2-point increase if the starting value is 0) at 2 consecutive follow-up visits.
| Months | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Time to Pain Progression (TTPP) | NA (NA to NA) | NA (NA to NA) |
Time to opiate use is defined as the time from date of randomisation to the date of first opiate use for cancer related pain.
| Months | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Time to Opiate Use | NA (NA to NA) | NA (NA to NA) |
Time from date of randomisation to date of first symptomatic skeletal-related event as defined by any of the following or a combination: * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). * Occurrence of spinal cord compression. * Orthopaedic surgical intervention for bone metastasis.
| Months | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Time to a Symptomatic Skeletal-Related Event (SSRE) | NA (NA to NA) | NA (NA to NA) |
The time to PFS2 is defined as the time from date of randomisation to date of second progression on next-line (immediately after study treatment) anticancer therapy or death, whichever occurs earlier.
| Months | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Time to Second Progression or Death (PFS2) | 28.71 (NA to NA) | NA (NA to NA) |
All BPI-SF pain items including "worst pain" are scored on a 0-10 numeric rating scale (NRS) with 0=No Pain and 10=Worst Pain Imaginable. The pain severity domain consists of 4 items (item #3, item #4, item #5, and item #6) which assess pain at its "worst," "least," "average," and "now" (current pain) respectively on the 11-point NRS. The overall pain severity score is calculated for each patient/visit as the mean of the individual non-missing items. The pain interference domain score is a mean of 7 items: general activity (item #9A), mood (item #9B), walking ability (item #9C), normal work (item #9D), relations with other people (item #9E), sleep (item #9F), and enjoyment of life (item #9G), each scored on an 11-point NRS from 0 (Does not interfere) to 10 (Completely interferes). BPI-SF worst pain, pain severity and pain interference score changes can be a minimum of -10 and a maximum of 10. A negative change from baseline value indicates improvement.
| Score | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Change from baseline in BPI-SF worst pain - Week 5 | -0.70 (-1.25 to -0.15) | -0.66 (-1.13 to -0.19) |
| Change from baseline in BPI-SF worst pain - Week 9 | -1.37 (-2.05 to -0.69) | -0.61 (-1.11 to -0.12) |
| Change from baseline in BPI-SF worst pain - Week 13 | -1.42 (-2.16 to -0.69) | -0.35 (-0.69 to -0.01) |
| Change from baseline in BPI-SF worst pain - Week 17 | -1.22 (-2.01 to -0.43) | -0.38 (-0.94 to 0.18) |
| Change from baseline in BPI-SF worst pain - Week 21 | -1.06 (-1.71 to -0.40) | -0.63 (-1.20 to -0.06) |
| Change from baseline in BPI-SF worst pain - Week 25 | -0.95 (-1.63 to -0.27) | -0.74 (-1.33 to -0.16) |
| Change from baseline in BPI-SF worst pain - Week 29 | -1.24 (-1.88 to -0.60) | -0.26 (-0.84 to 0.33) |
| Change from baseline in BPI-SF worst pain - Week 33 | -0.78 (-1.66 to 0.09) | -0.66 (-1.31 to -0.01) |
| Change from baseline in BPI-SF worst pain - Week 37 | -0.61 (-1.25 to 0.03) | -0.59 (-1.19 to 0.02) |
| Change from baseline in BPI-SF worst pain - Week 41 | -0.10 (-1.09 to 0.88) | -0.43 (-0.97 to 0.10) |
| Change from baseline in BPI-SF worst pain - Week 45 | -0.46 (-1.47 to 0.56) | -0.19 (-0.74 to 0.36) |
| Change from baseline in BPI-SF worst pain - Week 49 | 0.11 (-0.81 to 1.02) | -0.06 (-0.59 to 0.47) |
| Change from baseline in BPI-SF overall pain severity score - Week 5 | -0.51 (-0.98 to -0.05) | -0.56 (-0.98 to -0.13) |
| Change from baseline in BPI-SF overall pain severity score - Week 9 | -1.12 (-1.65 to -0.60) | -0.54 (-1.00 to -0.08) |
| Change from baseline in BPI-SF overall pain severity score - Week 13 | -1.21 (-1.78 to -0.63) | -0.31 (-0.60 to -0.02) |
| Change from baseline in BPI-SF overall pain severity score - Week 17 | -1.02 (-1.67 to -0.38) | -0.34 (-0.85 to 0.16) |
| Change from baseline in BPI-SF overall pain severity score - Week 21 | -0.87 (-1.39 to -0.35) | -0.57 (-1.09 to -0.06) |
| Change from baseline in BPI-SF overall pain severity score - Week 25 | -0.81 (-1.37 to -0.25) | -0.68 (-1.22 to -0.14) |
| Change from baseline in BPI-SF overall pain severity score - Week 29 | -0.94 (-1.46 to -0.42) | -0.26 (-0.71 to 0.18) |
| Change from baseline in BPI-SF overall pain severity score - Week 33 | -0.72 (-1.36 to -0.08) | -0.63 (-1.20 to -0.06) |
| Change from baseline in BPI-SF overall pain severity score - Week 37 | -0.43 (-0.90 to 0.03) | -0.51 (-0.94 to -0.08) |
| Change from baseline in BPI-SF overall pain severity score - Week 41 | -0.19 (-0.74 to 0.36) | -0.42 (-0.83 to -0.01) |
| Change from baseline in BPI-SF overall pain severity score - Week 45 | -0.45 (-1.12 to 0.22) | -0.26 (-0.65 to 0.12) |
| Change from baseline in BPI-SF overall pain severity score - Week 49 | -0.01 (-0.52 to 0.50) | -0.21 (-0.64 to 0.21) |
| Change from baseline in BPI-SF overall pain interference score - Week 5 | -0.21 (-0.75 to 0.33) | -0.30 (-0.71 to 0.12) |
| Change from baseline in BPI-SF overall pain interference score - Week 9 | -0.88 (-1.41 to -0.35) | -0.33 (-0.83 to 0.17) |
| Change from baseline in BPI-SF overall pain interference score - Week 13 | -0.98 (-1.53 to -0.42) | -0.14 (-0.44 to 0.15) |
| Change from baseline in BPI-SF overall pain interference score - Week 17 | -0.83 (-1.47 to -0.19) | -0.16 (-0.68 to 0.37) |
| Change from baseline in BPI-SF overall pain interference score - Week 21 | -0.70 (-1.24 to -0.15) | -0.31 (-0.84 to 0.21) |
| Change from baseline in BPI-SF overall pain interference score - Week 25 | -0.53 (-1.14 to 0.09) | -0.42 (-0.97 to 0.13) |
| Change from baseline in BPI-SF overall pain interference score - Week 29 | -0.78 (-1.33 to -0.23) | 0.02 (-0.37 to 0.42) |
| Change from baseline in BPI-SF overall pain interference score - Week 33 | -0.70 (-1.43 to 0.03) | -0.35 (-0.94 to 0.24) |
| Change from baseline in BPI-SF overall pain interference score - Week 37 | -0.21 (-0.68 to 0.26) | -0.09 (-0.50 to 0.31) |
| Change from baseline in BPI-SF overall pain interference score - Week 41 | -0.05 (-0.59 to 0.49) | -0.18 (-0.57 to 0.21) |
| Change from baseline in BPI-SF overall pain interference score - Week 45 | -0.36 (-1.01 to 0.30) | -0.13 (-0.52 to 0.26) |
| Change from baseline in BPI-SF overall pain interference score - Week 49 | 0.09 (-0.39 to 0.57) | -0.15 (-0.56 to 0.26) |
The following measures are calculated from the FACT-P questionnaire, the resulting value is the total score for the associated questions or scaled scores: * Physical well-being subscale (PWB) (Questions GP1 to GP7) * Social/family well-being subscale (SWB) (Questions GS1 to GS7) * Emotional well-being subscale (EWB) (Questions GE1 to GE6) * Functional well-being subscale (FWB) (Questions GF1 to GF7) * Prostate cancer subscale (PCS) (Questions C2, C6, P1 to P8, BL2 and BL5) The scores range from 0 ("Not at all") to 4 ("Very much") for positively phrased questions, and from 0 ("Very much") to 4 ("Not at all") for negatively phrased questions. Total FACT-P score is the sum of PWB, SWB, EWB, FWB and PCS. FACT-P total score changes can be a minimum of -156 and a maximum of 156. A positive value indicates improvement. FACT-G total score is the sum of PWB, SWB, EWB and FWB. FACT-G Total score changes can be a minimum of -108 and a maximum of 108. A positive value indicates improvement.
| Score | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| Change from baseline in FACT-P Total - Week 5 | -4.43 (-11.40 to 2.54) | -0.84 (-4.92 to 3.25) |
| Change from baseline in FACT-P Total - Week 9 | -4.95 (-12.69 to 2.79) | 1.00 (-4.80 to 6.79) |
| Change from baseline in FACT-P Total - Week 13 | -1.51 (-7.95 to 4.92) | -3.07 (-8.49 to 2.36) |
| Change from baseline in FACT-P Total - Week 17 | -1.82 (-10.00 to 6.36) | -3.51 (-9.63 to 2.60) |
| Change from baseline in FACT-P Total - Week 21 | -6.60 (-15.08 to 1.88) | -0.54 (-7.07 to 6.00) |
| Change from baseline in FACT-P Total - Week 25 | -6.55 (-16.46 to 3.36) | -1.68 (-8.30 to 4.95) |
| Change from baseline in FACT-P Total - Week 29 | -1.32 (-11.86 to 9.22) | 0.62 (-6.28 to 7.53) |
| Change from baseline in FACT-P Total - Week 33 | -7.23 (-17.13 to 2.68) | -0.75 (-6.97 to 5.46) |
| Change from baseline in FACT-P Total - Week 37 | -3.21 (-11.48 to 5.07) | -4.87 (-11.95 to 2.22) |
| Change from baseline in FACT-P Total - Week 41 | -7.16 (-15.95 to 1.63) | 0.47 (-6.04 to 6.99) |
| Change from baseline in FACT-P Total - Week 45 | -8.28 (-17.49 to 0.92) | -1.69 (-7.76 to 4.39) |
| Change from baseline in FACT-P Total - Week 49 | -9.78 (-17.36 to -2.21) | -1.35 (-6.72 to 4.02) |
| Change from baseline in FACT-G Total - Week 5 | -4.85 (-9.84 to 0.14) | -1.75 (-4.92 to 1.42) |
| Change from baseline in FACT-G Total - Week 9 | -4.55 (-10.27 to 1.17) | -0.07 (-3.80 to 3.66) |
| Change from baseline in FACT-G Total - Week 13 | -2.43 (-6.97 to 2.11) | -3.79 (-7.41 to -0.16) |
| Change from baseline in FACT-G Total - Week 17 | -2.45 (-8.19 to 3.29) | -4.30 (-7.98 to -0.62) |
| Change from baseline in FACT-G Total - Week 21 | -5.26 (-11.49 to 0.98) | -2.10 (-6.40 to 2.20) |
| Change from baseline in FACT-G Total - Week 25 | -6.23 (-13.50 to 1.04) | -3.45 (-8.39 to 1.49) |
| Change from baseline in FACT-G Total - Week 29 | -2.26 (-10.15 to 5.63) | -1.35 (-6.27 to 3.57) |
| Change from baseline in FACT-G Total - Week 33 | -6.15 (-13.40 to 1.09) | -2.75 (-7.38 to 1.87) |
| Change from baseline in FACT-G Total - Week 37 | -1.32 (-7.26 to 4.62) | -5.14 (-10.32 to 0.04) |
| Change from baseline in FACT-G Total - Week 41 | -5.72 (-12.30 to 0.86) | -1.08 (-5.90 to 3.75) |
| Change from baseline in FACT-G Total - Week 45 | -5.70 (-12.48 to 1.08) | -2.27 (-6.78 to 2.24) |
| Change from baseline in FACT-G Total - Week 49 | -7.78 (-13.34 to -2.22) | -1.51 (-5.13 to 2.11) |
Collected over Adverse events with an onset date, or worsen, on or after the date of first dose and up to and including 30 days following discontinuation of randomised treatment. Assessed from date of randomisation to data cut off (China DCO): 22Jan2024 (Approx. 2 years 7 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | 18/54 (33.3%) | 23/54 (42.6%) | 53/54 (98.1%) |
| Placebo bd + Abiraterone 1000 mg qd | 16/56 (28.6%) | 21/56 (37.5%) | 54/56 (96.4%) |
| Event | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| PneumoniaInfections and infestations | 4/54 | 0/56 |
| CataractEye disorders | 2/54 | 0/56 |
| DeathGeneral disorders | 2/54 | 1/56 |
| Covid-19Infections and infestations | 2/54 | 2/56 |
| Urinary tract infectionInfections and infestations | 2/54 | 0/56 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/54 | 2/56 |
| Abdominal painGastrointestinal disorders | 1/54 | 0/56 |
| DuodenitisGastrointestinal disorders | 1/54 | 0/56 |
| Gastric ulcerGastrointestinal disorders | 1/54 | 0/56 |
| Gastritis erosiveGastrointestinal disorders | 1/54 | 0/56 |
| Event | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 42/54 | 18/56 |
| Blood bilirubin increasedInvestigations | 14/54 | 15/56 |
| Alanine aminotransferase increasedInvestigations | 11/54 | 14/56 |
| Lymphocyte count decreasedInvestigations | 13/54 | 5/56 |
| HyperlipidaemiaMetabolism and nutrition disorders | 9/54 | 13/56 |
| HypokalaemiaMetabolism and nutrition disorders | 7/54 | 13/56 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 10/54 | 12/56 |
| Aspartate aminotransferase increasedInvestigations | 11/54 | 11/56 |
| White blood cell count decreasedInvestigations | 11/54 | 3/56 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 11/54 | 11/56 |
Full analysis set
| Age, Continuous(Years) | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd | Total |
|---|---|---|---|
| Mean | 69.5 ± 8.2 | 68.9 ± 7.6 | 69.2 ± 7.9 |
| Age, Customized(Participants) | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd | Total |
|---|---|---|---|
| <65 | 13 | 17 | 30 |
| >=65 | 41 | 39 | 80 |
| Sex/Gender, Customized(Participants) | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd | Total |
|---|---|---|---|
| Male | 54 | 56 | 110 |
| Race/Ethnicity, Customized(Participants) | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd | Total |
|---|---|---|---|
| HISPANIC OR LATINO | 0 | 0 | 0 |
| NOT HISPANIC OR LATINO | 54 | 56 | 110 |
| NOT REPORTED | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd | Total |
|---|---|---|---|
| ASIAN | 54 | 56 | 110 |
| Region of Enrollment(Participants) | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd | Total |
|---|---|---|---|
| China | 54 | 56 | 110 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2021 to primary completion in Jan 2024, 30 months.
Results were first posted in Jun 2025, 1 year 5 months after primary completion. A results delay was requested in Jan 2025.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 30 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib